CA2573541A1 - Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb> - Google Patents

Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb> Download PDF

Info

Publication number
CA2573541A1
CA2573541A1 CA002573541A CA2573541A CA2573541A1 CA 2573541 A1 CA2573541 A1 CA 2573541A1 CA 002573541 A CA002573541 A CA 002573541A CA 2573541 A CA2573541 A CA 2573541A CA 2573541 A1 CA2573541 A1 CA 2573541A1
Authority
CA
Canada
Prior art keywords
composition
glycan
immunoglobulins
antibody
glycans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573541A
Other languages
English (en)
Inventor
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycofi Inc
Original Assignee
Glycofi, Inc.
Tillman U. Gerngross
Huijuan Li
Stefan Wildt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycofi, Inc., Tillman U. Gerngross, Huijuan Li, Stefan Wildt filed Critical Glycofi, Inc.
Publication of CA2573541A1 publication Critical patent/CA2573541A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
CA002573541A 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb> Abandoned CA2573541A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US58991304P 2004-07-21 2004-07-21
US58993704P 2004-07-21 2004-07-21
US60/589,913 2004-07-21
US60/589,937 2004-07-21
PCT/US2005/025662 WO2006014685A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme de type man3glcnac2

Publications (1)

Publication Number Publication Date
CA2573541A1 true CA2573541A1 (fr) 2006-02-09

Family

ID=35285633

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573541A Abandoned CA2573541A1 (fr) 2004-07-21 2005-07-19 Immunoglobulines comprenant principalement une glycoforme de type man<sb>3</sb>glcnac<sb>2</sb>

Country Status (5)

Country Link
EP (1) EP1771480A1 (fr)
JP (1) JP2008512354A (fr)
AU (1) AU2005269765A1 (fr)
CA (1) CA2573541A1 (fr)
WO (1) WO2006014685A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CA2665644A1 (fr) 2006-10-12 2008-05-29 Genentech, Inc. Anticorps de la lymphotoxine-alpha
US20100081172A1 (en) 2008-09-26 2010-04-01 Eureka Therapeutics, Inc. N-Glycans and Uses Thereof
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
HUE051749T2 (hu) 2015-03-02 2021-03-29 Conagen Inc Labirintusgomba mikroorganizmusokból származó szabályozó elemek
AU2017235543B2 (en) 2016-03-16 2020-05-14 Conagen, Inc. Production of proteins in labyrinthulomycetes
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
US10457970B2 (en) 2016-11-01 2019-10-29 Conagen Inc. Expression of modified glycoproteins and glycopeptides
AU2022244103A1 (en) * 2021-03-23 2023-10-05 Glycoera Ag Mannose 3 glycan-mediated protein degradation
EP4314053A2 (fr) * 2021-03-23 2024-02-07 Glycorea AG Dégradation de protéine à médiation par glycane

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625756B2 (en) * 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
JP4820055B2 (ja) * 2001-12-27 2011-11-24 グライコフィ， インコーポレイテッド 哺乳動物型糖質構造を操作するための方法

Also Published As

Publication number Publication date
EP1771480A1 (fr) 2007-04-11
WO2006014685A1 (fr) 2006-02-09
JP2008512354A (ja) 2008-04-24
AU2005269765A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
US20060029604A1 (en) Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060024292A1 (en) Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
US20060034829A1 (en) Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform
US20060034830A1 (en) Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060034828A1 (en) Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
CA2573745A1 (fr) Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
US20060257399A1 (en) Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform
CA2573842A1 (fr) Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2
WO2006071856A2 (fr) Immunoglobulines comprenant principalement une glycoforme man5glcnac2
CA2573541A1 (fr) Immunoglobulines comprenant principalement une glycoforme de type man&lt;sb&gt;3&lt;/sb&gt;glcnac&lt;sb&gt;2&lt;/sb&gt;
US20090226464A1 (en) Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform
CA2620515A1 (fr) Immunoglobulines comprenant principalement une glycoforme glcnacman3glcnac2
CA2590441A1 (fr) Immunoglobulines comprenant principalement un glycoforme galglcnacman5glcnac2
CA2573554A1 (fr) Immunoglobulines comprenant principalement une glycoforme man&lt;sb&gt;5&lt;/sb&gt;glcnac&lt;sb&gt;2&lt;/sb&gt;
CA2573864A1 (fr) Immunoglobulines comprenant principalement une glycoforme glcnacman&lt;sb&gt;5&lt;/sb&gt;glcnac&lt;sb&gt;2&lt;/sb&gt;
CN101001875A (zh) 主要包含man5glcnac2糖形的免疫球蛋白

Legal Events

Date Code Title Description
FZDE Dead